As of 1:02pm ET
| -0.15 / -0.70%|
Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the following segments: Specialty Brands, Specialty Generics, and Nuclear Imaging. The Specialty Brands segment produces and markets branded pharmaceuticals and biopharmaceuticals. The Specialty Generics segment engages in the production of specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Nuclear Imaging segment manufactures and markets radiopharmaceuticals. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Staines-Upon-Thames, the United Kingdom.
|Mark C. Trudeau||President, Chief Executive Officer & Director|
|Frank Scholz||Senior Vice President-Global Operations|
|Matthew K. Harbaugh||Chief Financial Officer & Senior Vice President|
|Steven Romano||Chief Scientific Officer & Senior Vice President|
|Karen Sheehy||Chief Compliance Officer|